Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn’s Disease Patients
- Wednesday, September 14, 2022, 7:14
- PR Newswire
- Add a comment
SAN DIEGO, Sept. 14, 2022 /PRNewswire/ — Prometheus Laboratories Inc. (“Prometheus”) today announced its partnership with Takeda Pharmaceutical Company Limited (“Takeda”) to nationally launch CDPATH, an innovative prognostic tool for Crohn’s disease (CD) patients. CDPATH is a…
About the Author
admin has written 20655 stories on this site.